SOA Wealth Advisors’s Astria Therapeutics ATXS Stock Holding History

SOA Wealth Advisors’s Portfolio ATXS Stock Details ATXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-7	Closed	-$52	–	911
2023 Q3	$52	Hold	7	–	–	﹤0.01%	922
2023 Q2	$58	Hold	7	–	–	﹤0.01%	922
2023 Q1	$93	Hold	7	–	–	﹤0.01%	939
2022 Q4	$104	Hold	7	–	–	﹤0.01%	939
2022 Q3	$0	Hold	7	–	–	﹤0.01%	822
2022 Q2	$0	Hold	7	–	–	﹤0.01%	814
2022 Q1	$0	Buy	+7	New	+$42	﹤0.01%	897

Other funds holding ATXS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

SOA Wealth Advisors's ATXS Position: Q4 2023 in Review

SOA Wealth Advisors sold out of Astria Therapeutics (ATXS) in Q4 2023, closing a stake of 7 shares — an estimated $52 sold.

SOA Wealth Advisors first reported a position in ATXS in Q1 2022 and held it in 7 quarters. The position peaked at $104 in Q4 2022. 80 funds tracked by Wall St. Rank hold ATXS as of Q4 2023.

SOA Wealth Advisors reported no remaining Astria Therapeutics position as of Q4 2023 after selling out during the quarter.
SOA Wealth Advisors sold 7 Astria Therapeutics shares in Q4 2023, an estimated $52.
SOA Wealth Advisors first reported a position in Astria Therapeutics in Q1 2022 and held it in 7 quarters.
SOA Wealth Advisors's Astria Therapeutics position peaked at $104 in Q4 2022.
80 funds tracked by Wall St. Rank held Astria Therapeutics as of Q4 2023.

Based on SOA Wealth Advisors's 13F filing for Q4 2023, filed 10 Jan 2024.